Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Esad1, Do you really think it will be more beneficial financially for XXII to do an exclusive licence...been there before with BAT and it didn't work too well but this time it's different tho ..
"Right now I would guess Henry is negotiating with Japan Tobacco and some Chinese about an exclusive license."
These comments will help the Agency identify and address priorities related to the use of therapeutic nicotine for combustible tobacco product cessation.
DATES: Submit either electronic or written comments by April 16, 2018
Confusing, does that mean the FDA hasn't reached a decision yet ? and if they did, why do they need to set this up ??
Am I missing something?
We know the truth, We understand our investment in XXII, We know the patents, We know the technology, We know what is about to happened with the FDA decision and the worldwide ramification of it...
We don't need a babysitter cheerleader to remind us of our great and smart decision to invest in XXII and we know we will get richer soon from our investment...
....WE ARE GOING TO TH MOON!!!!!
THE RESEARCH
In 2006, Vector Tobacco sponsored a multi-center Phase II smoking-cessation clinical trial to evaluate the effectiveness of Quest® alone or in combination with nicotine replacement therapy (Becker et al. 2008). This trial was performed under Vector’s Investigational New Drug Application (IND) filed with the FDA in 2004. After conveying that it intended to proceed with Phase III clinical trials, Vector Group Ltd. announced that Vector Tobacco was no longer pursuing FDA approval of its smoking cessation aid in development. Accordingly, 22nd Century’s licenses to all affiliates of Vector Group Ltd. were terminated. Subsequently (in 2008) through binding arbitration, 22nd Century obtained rights to use and reference at the FDA all data in Vector’s IND, including all results from the Phase II clinical trial, relating to cigarettes containing 22nd Century’s proprietary tobacco. 22nd Century no longer has any type of relationship with Liggett Group or Vector Tobacco.
From 2005 to 2009, 22nd Century partnered again with NCSU and with other public institutions for further R&D that included the cloning of additional nicotine biosynthesis genes: the Nara Institute of Science and Technology, Nara Japan (NAIST) and the National Research Council of Canada, Plant Biotechnology Institute, Saskatoon Canada (NRC). These contracted R&D partners, NCSU, NAIST and NRC, were first to (i) clone the key nicotine biosynthesis genes and several transcription factor genes that regulate expression of all nicotine biosynthesis genes and (ii) demonstrate biochemical evidence of the function of these genes. The technology and exclusive related patent rights 22nd Century obtained from NAIST and NRC are keystones of 22nd Century’s intellectual property, representing the company’s second-generation technology that has significant advantages over the earlier technology licensed to Liggett Group and Vector Tobacco. Furthermore, 22nd Century’s technology can be employed so that the resulting tobacco plants are not genetically modified (GM).
22nd Century’s model of outsourcing R&D to world-renowned plant biotechnology centers has enabled 22nd Century to maintain strict control of its R&D costs, while providing the company broad access to large public institutions’ infrastructure and transdisciplinary expertise. As a result, 22nd Century has obtained exclusive rights to all key nicotine biosynthesis genes that can be regulated to produce viable commercial products with modified content of nicotine and tobacco-specific nitrosamines (TSNAs).
NAIST assigned various patent families to 22nd Century in 2010, including the NBB technology. Also in 2010, a University of Minnesota clinical trial, led by Dr. Dorothy Hatsukami who is a member of FDA’s Tobacco Products Scientific Advisory Committee known as TPSAC, demonstrated that VLN cigarettes (made exclusively with 22nd Century’s proprietary tobacco) used over a 6-week treatment period are effective for smoking cessation (Hatsukami et al. 2010). 22nd Century also completed development of an improved VLN cigarette to continue clinical trials with the company’s proprietary VLN cigarettes for use in smoking cessation.
http://www.xxiicentury.com/history/
Sorry I don't get the meaning of "The goal... $5 per by 5 weeks"
Does that mean $5 a share in 5 weeks??
Thanks
PERKER SAID
"Do I need to spell it out? If I did, I'd be working elsewhere. So here goes, we won't be giving up anything for Lent."
So read between the lines and I think today was only the beginning!
This is great news for XXII (they are all murders!!
Also great timing on this one!
Here is the link to the French article (just few xtra details)
http://www.cnct.fr/communiques-de-presse-44/le-scandale-du-filtergate-177.html
Perker
I do appreciate your post and looking forward Lent then..
Lent this year starts Wednesday February 14 (how can you do Lent on Valentine's day!! LOL )..and ends on Thursday March 29....We shall see...
Go XXII
....and...
Anandia Labs is 19% owned by CannaRoyalty Corp., an active investor and operator in the legal cannabis industry and a Canadian publicly-traded company (CSE:CRZ) (OTCQX: CNNRF).
Thanks rootus
Here is the link
A Federal Court has ordered Lorillard, Altria, Philip Morris USA, and ...
https://www.pressreader.com/usa/chicago-tribune/20180204/283257393322240
Makes all sense.Thanks easd1
esad1 thanks for your insight as usual.
Cause I was wondering if there was a "big deal" in the making, why do we need to go to this investor conference?
what's in it for us if we are already talking and/or trying to make a deal or even considering a buyout by a big co?
I think by now we have all the exposure needed and everybody who should know about us already know us.
TIA
This statement actually makes a valid point..so it shows there is a small market for Iqos...I am sure there is room for everybody ....
"Goto said he bought an Iqos because his wife wouldn’t let him smoke cigarettes inside their house and the neighbors didn’t like him standing around and smoking outside. Toshiyuki Itakura, just behind Goto, chimed in about smoking the device in public: “There doesn’t seem to be any harm.”
Thanks esad1
Philip Morris and any tobacco companies are never to be trusted. .Period!
"“Taken as a whole, it’s clear they do not have the sophistication to carry out adequate and well-controlled clinical trials,” said David Kessler, the FDA’s commissioner from 1990 to 1997, referring to the company. “I am not inferring any malicious intent here, just that they lack sophistication, because this is not their bread and butter.”
Yea right or maybe they just don't want to.....
NEWS OUT
22nd Century to Present at BIO CEO & Investor Conference
Today 9:50 AM ET (Business Wire)Print
22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company focused on tobacco harm reduction and hemp/cannabis research, announced today that the Company will present at the BIO CEO & Investor Conference at the New York Marriott Marquis on Monday, February 12, 2018 at 2:00 PM EST.
Henry Sicignano III, President and Chief Executive Officer of 22nd Century Group, will deliver a formal presentation and will discuss the Company's recent business highlights and updates. Mr. Sicignano will also be available for one-on-one meetings with investors at the conference.
Now in its 20th year, the BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and select private biotech companies.
That news!!.....not really a "new" news tho.. but it helps and of course the share price reacted negatively on high volume at the end ..
FDA Remains Firmly Committed to Nicotine Reduction in Cigarettes
Today 3:41 PM ET (Business Wire)Print
22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company focused on tobacco harm reduction, reports recent activity relevant to the nicotine reduction mandate planned by the US Food and Drug Administration (FDA) .
In July 2017, FDA Commissioner Scott Gottlieb, M.D., announced the FDA's plan to limit nicotine in cigarettes to minimally or non-addictive levels. In his announcement, Dr. Gottlieb explained that if nicotine - long known as the primary addictive component of cigarettes - were reduced, smokers would lose their addiction to cigarettes and would then be free to choose when and how often to smoke. An equally important component in FDA's announced plan is to provide current smokers who are unable or unwilling to quit using nicotine with other, less harmful means to obtain it.
Prominent health advocacy associations have endorsed FDA's plan to dramatically reduce nicotine in cigarettes to minimally addictive or non-addictive levels and to provide "demonstrably less hazardous" (non-combustible) products for the subset of smokers who are unable or unwilling to quit. On October 13, 2017, the heads of the Cancer Action Network, American Heart Association, American Lung Association, Campaign for Tobacco-Free Kids and the Truth Initiative co-authored a letter to Dr. Gottlieb and the FDA urging the agency to enact a nicotine mandate as promptly as possible: "We support the objective of reducing the level of nicotine in cigarettes to render them minimally or non-addictive... It is critical that FDA begin action promptly, and set a firm deadline for completing, a Final Rule to reduce the levels of nicotine in cigarettes."
On January 23, 2018, The National Academies of Sciences, Engineering, and Medicine (NASEM) published an independent report evaluating the available scientific evidence addressing the short- and long-term health effects related to the use of electronic nicotine delivery systems (ENDS), such as e-cigarettes. While the NASEM report raised some concerns, the authors found conclusive evidence that switching exclusively to e-cigarettes "reduces users' exposure to numerous toxicants and carcinogens present in combustible tobacco cigarettes." The report also found substantial evidence that "nicotine intake from e-cigarette devices among experienced adult users can be comparable to that from combustible tobacco cigarettes." These two conclusions strengthen support for the FDA's proposed standard to: 1) reduce the nicotine content in cigarettes, and 2) provide current cigarette smokers who will not quit nicotine, with less harmful means to obtain it.
In a statement on the FDA's website, Dr. Gottlieb said, "the report finds that current smokers who completely switch to e-cigarettes may see improved short-term health outcomes." Responding to comments on the NASEM report that were posted on Twitter, Dr. Gottlieb made it clear that approved ENDS products are only part of the FDA plan, "We are pursuing a market where we use the product standard to render combustible cigs minimally or non-addictive."
On January 25, 2018, Dr. Gottlieb continued to trumpet the FDA's plan in a speech at the World Economic Conference in Davos, Switzerland. Stating that the smoking rate in the United States is too high, Dr. Gottlieb explained "we wish to reduce it greatly through our proposal to reduce nicotine in combustible cigarettes to minimally/non-addictive levels."
"22nd Century's Very Low Nicotine tobacco technology demonstrates that the FDA's plan to dramatically reduce nicotine in cigarettes is technologically feasible," explained James E. Swauger, PhD, Senior Vice President of Science and Regulatory Affairs for 22nd Century Group. "The letter to the FDA from public health associations, together with the NASEM report on e-cigarettes, highlight the growing public and scientific consensus that the FDA's planned nicotine reduction mandate is timely, practical, and urgently needed.
....."Look at the stocks she bought"...
Yea I would have thought better if she had bought XXII
Thanks esad1
I could not locate the article from 2015 but came upon this one from 2015 as well , very interesting read..
If people smoke for the nicotine but die from the tar arising from tobacco combustion, why not disassociate the two? We are increasingly convinced that reducing the nicotine content of combustible-tobacco products would undercut the motivation to smoke, that young people who continued to experiment with cigarettes would not become dependent on them, and that adult smokers would either get their nicotine from another source that is markedly safer or quit using nicotine altogether.
Smoking kills half the people who engage in it long term, robbing them of 10 to 15 years of life, according to the Centers for Disease Control and Prevention. Given the size of the current population of U.S. smokers, we can expect at least 20 million Americans to die prematurely if they continue to smoke. Reducing the nicotine content of combustible tobacco to levels that will not sustain dependence seems to us to be the most promising regulatory policy option for preventing those 20 million premature deaths.
http://www.nejm.org/doi/full/10.1056/NEJMp1509510
Thanks brooklyn13..
It never made any sense to me but even when XXII was producing high nicotine level cigarettes never made any sense (to me).
Glad they are out of it now.....
"22nd Century ending super premium, high-nicotine cigarette production "
http://www.journalnow.com/business/nd-century-ending-superpremium-high-nicotine-cigarette-production/article_06b5552f-e61e-588a-bcc6-e3e45d09f58c.html
Justfactsmam you said
"Ironically, as another "choice" in the mix...supercharging tobacco with V"High"N...could satisfy nicotine addiction (one cig?) and reduce ingestion of carcinogens by those who wish to continue to smoke!"
This is a concept I have problem to wrap my head around
I am not a smoker but I would think a high nicotine cigarette would just get me more addicted no? and therefor want to smoke more..
Also wanted to thank the few people here (you know who you are) participating this week-end in a back and forth discussion on XXII instead of posting BS or crazy predictions.
What To Make Of The FDA Vote That Rocked Philip Morris
1/25/18 3:26 PM ET (Benzinga)Print
What Happened
Philip Morris International Inc. (NYSE: PM) plummeted 6 percent intraday Thursday after the U.S. Food and Drug Administration’s Tobacco Products Scientific Advisory Committee rejected one of two claims surrounding its modified risk tobacco product.
Why It's Important
The IQOS — a tobacco heating system — mitigates consumer exposure to harmful chemicals but fails to demonstrate a substantial reduction in user mortality or morbidity, the FDA panel said.
Altria Group Inc (NYSE: MO) also fell 4 percent on the news, while 22nd Century Group Inc (NYSE: XXII) popped 7.6 percent.
Despite the market’s pessimism, Street analysts defended Philip Morris and its potential to secure authorization for the claims.
Height Securities analyst Stefanie Miller reminded investors that the MRTP case is only the second that the FDA panel has ever considered, and committee recommendations are non-binding.
What's Next
“We still think FDA will ultimately approve the PMTA as soon as next month and MRTP later in the summer for IQOS,” Miller said in a note.
Piper Jaffray agreed, noting that the regulatory body does not appear to present insurmountable roadblocks.
“While the FDA's TPSAC (scientific committee) meeting has yet to conclude, we consider its strongly favorable vote on one potential modified risk claim to be positive,” analyst Michael Lavery said in a midday note. “... We believe this vote gives the FDA the open door it needs to approve a modified risk claim for IQOS, which we believe it is still likely to do.”
The FDA would need to renew any approval it grants to IQOS, which renders its impending ruling impermanent and is seen to lower the probability of rejection.
Lavery also anticipates a favorable FDA ruling on marketing authorization.
Hedge fund says cannabis stocks will either collapse or we should all move to Canada and grow pot
https://www.cnbc.com/2018/01/25/lakewood-hedge-fund-short-on-canopy-growth-aurora-cannabis.html
On my portfolio news this morning
Should you buy stock in Boeing, Halliburton, Netflix, NVIDIA or 22nd Century Group Inc?
Today 9:31 AM ET (PR NewsWire)Print
InvestorsObserver issues critical PriceWatch Alerts for BA, HAL, NFLX, NVDA, and XXII.
To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link.
-- BA: https://www.investorsobserver.com/pr-stocks-lp/?stocksymbol=BA&prnumber=12220180
-- HAL: https://www.investorsobserver.com/pr-stocks-lp/?stocksymbol=hal&prnumber=12220180
-- NFLX: https://www.investorsobserver.com/pr-stocks-lp/?stocksymbol=NFLX&prnumber=12220180
-- NVDA: https://www.investorsobserver.com/pr-stocks-lp/?stocksymbol=nvda&prnumber=12220180
-- XXII: https://www.investorsobserver.com/pr-stocks-lp/?stocksymbol=XXII&prnumber=12220180
(Note: You may have to copy this link into your browser then press the [ENTER] key.)
InvestorsObserver's PriceWatch Alerts are based on our proprietary scoring methodology. Each stock is evaluated based on short-term technical, long-term technical and fundamental factors. Each of those scores is then combined into an overall score that determines a stock's overall suitability for investment
Yes "Fund a study" what is there to study ?? just look at the other states that have legalized marijuana or medical and learn .
Just more funding money wasted....
And you are right everybody is already smoking it..
I live in Queens NY and I cannot go a day without walking down the street and smelling it many times a day, same for in Manhattan...
Actually Gov Cuomo is thinking about legalizing recreational marijuana in NY state...It's a first step in the right direction.....
Gov. Cuomo Proposes Study of Recreational Marijuana Legalization
Gov. Andrew Cuomo wants New York to fund a study of the possible impact of legalizing recreational marijuana in the state, the Democratic governor said at his annual budget address in Albany on Tuesday afternoon. He also introduced several other proposals including a possible surtax on pharmaceutical company sales of opioid medications, and a tax on companies that sell over the internet.
https://www.law.com/newyorklawjournal/sites/newyorklawjournal/2018/01/16/gov-cuomo-proposes-study-of-recreational-marijuana-legalization/?slreturn=20180018153901
Talking about revenue.....
"Colorado Cannabis Sales Hit $1.49 Billion In 2017: Taxes Up To $247 Million, Medical Sales Down To $420 Million"
https://www.benzinga.com/news/18/01/11047865/colorado-cannabis-sales-hit-1-49-billion-in-2017-taxes-up-to-247-million-medical
LOOK EVERYONE
Gotta watch
Rep. Earl Blumenauer speaks after report of Sessions' plan to rescind pot policy
From LA TIMES. Today...,
California's state Bureau of Cannabis Control, which on Monday began processing hundreds of applications for businesses seeking to legally grow, transport and sell marijuana. showed no sign of slowing after Sessions' announcement.
The bureau's chief, Lori Ajax, vowed to continue issuing permits "while defending our state's laws to the fullest extent."
http://beta.latimes.com/politics/la-na-pol-pot-sessions-20180104-story.html
What Sessions Move on Marijuana Means for Hemp, CBD
By WholeFoods Magazine Staff - January 4, 2018
Attorney General Jeff Sessions’ decision to rescind the 2013 Obama administration memo saying it would not stand in the way of states that legalize marijuana may scare investors, but should not affect hemp-based businesses or the retailers that sell their products.
That’s the opinion of Sean Murphy, founder and publisher of Hemp Business Journal.
“CNN calls it a seismic shift—I don’t think it is—but if it is then it’s only a seismic shift for marijuana companies—not hemp companies,” Murphy said.
“If a company is a ‘hemp-derived CBD’ company — as both CV Sciences and CW Hemp are—then it should not truly affect them much from a business/operative perspective but it may cause their investors to get jittery/nervous because they don’t understand that the Cole Memo applies to marijuana companies—not hemp companies,” Murphy said.
The Cole Memo was originally drafted by former US Attorney General James M. Cole and de-prioritized the use of funds to enforce cannabis prohibition under the Controlled Substances Act towards a more hands-off approach.
For hemp companies, the more impactful legal item in this realm of regulations and oversight is the DEA New Drug Code for Marihuana extracts. Oral Arguments between HIA/Hoban Law vs the DEA are set for February.
The ruling from this will have a more direct impact as it relates specifically to DEA stepping its regulatory control from the marijuana regulatory environment into the hemp regulatory environment, Murphy noted.
One Wall Street analyst downplayed the impact of the decision, saying the legalization movement won’t be affected, CNBC reported.
“We don’t view this as terribly disruptive, as enforcement decisions will seemingly be left to state-level AG’s,” Cowen analyst Vivien Azer wrote Thursday. “In legal adult use cannabis states, given the tax revenue generation, we believe local governments and AG’s are largely on-board with legalization.”
Colorado was among the first to legalize marijuana and has raised nearly $200 million in pot revenue last year alone. Just this week, recreational use of marijuana became legal in California.
Source: https://wholefoodsmagazine.com/news/breaking-news/sessions-move-marijuana-means-hemp-cbd/
Bernie Sanders just poured cold water on Jeff Sessions’ anti-pot crusade
http://thepoliticalorder.com/bernie-sanders-just-poured-cold-water-jeff-sessions-anti-pot-crusade/
BIG NEWS!! Jeff Sessions Won't End Legal Pot
John Stoehr • Jan. 4, 2018
The U.S. Department of Justice is not going to stop the sale of marijuana where legal. I repeat: This is not going to happen, not in a lasting meaningful way. Yes, individuals might be convicted, but a terrible decision to rescind the Obama-era rule allowing legalization to flourish is not a wholesale rollback of legal weed around the country.
If you believe that, you believe the federal government has far more power than it has, and you don't have much faith in democracy or the U.S. Constitution. This is not to say there won't be hurdles to overcome, but is to say the federal government cannot slow the pace of progress.
Let me start from the beginning.
The Associated Press broke the newsThursday, reporting that U.S. Attorney General Jeff Sessions is getting ready to cancel a policy from the previous administration that relaxed federal drug law enforcement. Under this rule, states moved quickly from decriminalization to legalization. California is the latest. Legal sales began there Jan. 1.
Before you rend your clothes and gnash your teeth, consider this, also from the Associated Press: Even as Sessions is formally eliminating the Obama-era rule, he is taking steps to "let federal prosecutors where pot is legal decide how aggressively to enforce federal marijuana law."
What does this suggest? That Sessions is getting what he wants: a federal government upholding the appearance of zero tolerance, while not doing much about it. (This is not Trump's position; his is unclear.) Sessions is delegating the hard work to locally based federal prosecutors who may or may not act, and while they have the power, they won't be quick to use that power, because using it would contravene the democratic will.
Remember that most laws are not federal. They are state laws. The Constitution enumerates a short list of powers for the U.S. government while delegating the rest. The founders balanced centralized power against state sovereignty and the right to self-government. States are where most policy innovation comes from, not the federal government. When it comes to policy innovation, the states are ahead of the feds.
There are limits to this. For a long time, the Bill of Rights did not apply to states. They could discriminate against (black) residents, and there was not much anyone could do to stop it. That's when civil rights advocates turned to the federal government, first to the U.S. Supreme Court and then the U.S. Congress. For a long time, from the Gilded Age to the end of the Vietnam War, progressivism's center of gravity was Washington.
For the last four decades or so, that center of gravity has increasingly grown diffuse as conservatives consolidated control of Washington and the federal courts. In recent years, progressives have turned less to the courts and more to elected bodies in states and big cities, pushing single issues like gay marriage, minimum wage increases, gun control and marijuana legalization. This grassroots approach is not only practical. It's in keeping with the American tradition. Top-down progress is good, but not as good, or as lasting, as progress from the bottom up.
Legalization is the product of democratic deliberation or popular referendum, so locally based federal prosecutors are keenly aware they must proceed with caution if they proceed at all. Yes, U.S. attorneys are appointed by a president with a penchant for authoritarianism. Someone somewhere might be arrested for breaking federal law. In the event that happens, that will set federal power face-to-face with state sovereignty and the people's will. Given 40 years of conservative jurisprudence, odds are the feds lose an embarrassing and easily avoided fight.
Sessions' decision may about optics more than policy, but even the optics are problematic. His decision stands against surveys showing most Americans don't think pot is worse than alcohol. As the Washington Monthly's Gilad Edelman noted, Trump is now tied to a very unpopular position.
But it reflects something else. The Republican Party has run out of ideas. It used to stand for limited government. But now, instead of being opposed to Big Government, Trump and the Republicans are embracing it, as long as Big Government cracks down on things conservatives don't like, such as reproductive rights, undocumented immigrants and pot.
Some argue that Obama's policy was a half-measure. It did not go far enough in changing America's absurd drug laws. That might be true, but it's also true that his "hands off" policy gave states the time and space to move ahead in ways preferable to residents of those states. That's slow painful progress but it's progress with staying power.
U.S. News & World Report
Rankings & Research
Colleges, cars, hospitals, doctors ... more
News & Opinion
Latest headlines and news you can use
News Education Health Money CarsReal Estate Travel
Copyright 2017 © U.S. News & World Report L.P.
https://www.usnews.com/opinion/thomas-jefferson-street/articles/2018-01-04/jeff-sessions-cant-stop-americas-march-to-marijuana-legalization?context=amp&__twitter_impression=true
Legal Weed Isn’t The Boon Small Businesses Thought It Would Be
As California opens its market Jan. 1, Washington state’s experience serves as a warning
https://fivethirtyeight.com/features/legal-weed-isnt-the-boon-small-businesses-thought-it-would-be/
Happy new year to all here..and especially Happy new-year California!
How legal marijuana will change California in 2018
https://www.salon.com/2017/12/31/how-legal-marijuana-will-change-california-in-2018/
Finally: War On Medical Marijuana Ends As Feds Lift The Ban
https://ushealthnote.com/2017/12/26/finally-war-on-medical-marijuana-ends-as-feds-lift-the-ban/
Got my greeting card too but it took me a while and 3 attends before succeeding at seeing the hidden message on the back of the card!
My eyes are not what they used to be lol
Value And Momentum Breakouts - 2017 End Of Year Report Card And Forecast
Some of the best stocks (80%+ YTD) selected this year using the Breakout Forecast include: Sangamo Therapeutics, Inc. (SGMO) +271.59%, RLJ Entertainment (RLJE) +99.48%, KEMET Corporation (KEM) +100.77%, XOMA Corporation (XOMA) +426.94%, Fusion Telecommunications International (FSNN) +120.48%, ION Geophysical (IO) +157.69%, 22nd Century Group (XXII) +157.28%, Abeona Therapeutics, Inc (ABEO) +175.00%, QuinStreet, Inc (QNST) +86.85%, Vital Therapies (VTL) +81.97%, Dicerna Pharmaceuticals (DRNA) +94.25%, Town Sports International Holdings (CLUB) +88.52%, Limelight Networks (LLNW) +89.47%, NL Industries (NL) +83.70%.
Disclosure: I am/we are long XXII.
Exposure.... exposure...
https://seekingalpha.com/article/4132318-value-momentum-breakouts-2017-end-year-report-card-forecast?ifp=0&app=1
Cigarette smoking has dropped so sharply among American teenagers that vaping and marijuana use are now more common, according to a national survey of adolescent drug use released Thursday
https://www.nytimes.com/2017/12/14/health/teen-drug-smoking.html
Kind of OT but to show you how the FDA is changing and adapting with new technology.
Found it on ONVO board (3D printing organs) I own shares..
Great reading in any case...
"statement by FDA Commissioner Scott Gottlieb, M.D., on FDA ushering in new era of 3D printing of medical products; provides guidance to manufacturers of medical devices"
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm587547.htm
I am not a trader more like a swing trader and definitely an investor..
Those shares were bought around 11 months ago at .90 so definitely not a trader. but I take action when opportunity arise .
I was just posting because it never happened to me before and thought someone could explain....Just sarted few months ago using thinkorswim from ameritrade
Best
Bought those shares at .90 so all good .. and I still have 7500 shares remaining at $1.90 average (but bought mostly under $1) so I am not sweating it.
all about discipline ....should have... could have ..I never regret my trades.. and I needed to free a little cash , we all have our story and our reasons...
best